The FDA approved AstraZeneca’s baxdrostat as Baxfendy, positioning it as the first drug in a new class of aldosterone synthase inhibitors for hypertension patients not adequately controlled on existing therapy. The approval was supported by results from the Phase III BaxHTN study, which met primary and secondary endpoints. Aldosterone synthase inhibition targets a different hypertension biology than more common medication classes, and it arrives as patent pressure grows across the class of cardiometabolic franchises. AstraZeneca says the label is for use in combination with other antihypertensive agents. Competition is already in view: Mineralys Therapeutics is flagged with a December 2026 PDUFA date for lorundrostat, setting up an early head-to-head question on efficacy and tolerability among aldosterone synthase inhibitor developers.